Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

Disease-modifying therapies in relapsing–remitting multiple sclerosis

Authors Gonzalez-Andrade JF, Alcaraz J

Published 6 July 2010 Volume 2010:6(1) Pages 365—373

DOI https://doi.org/10.2147/NDT.S11079

Review by Single-blind

Peer reviewer comments 2


Fabricio González-Andrade1, José Luis Alcaraz-Alvarez2

1Department of Medicine, Metropolitan Hospital, Quito, Ecuador; 2School of Medicine, University of Mayab, Merida, Mexico

Clinical question: What is the best current disease-modifying therapy for relapsing–remitting multiple sclerosis?

Results: The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-frequency subcutaneous interferon-β1a 44 μg three times per week.

Implementation: The pitfalls in treatment of MS can be avoided by remembering the following points:

• The most effective therapy to prevent or delay the appearance of permanent neurological disability with the fewest side effects should be chosen, and treatment should not be delayed.

• Adherence to treatment should be monitored closely, and needs comprehensive patient information and education to establish long-term adherence, which is a critical determinant of long-term outcome.

• The correct approach to the disease includes disease management, symptom management, and patient management. A combination of tools is necessary to ease the various symptoms, which fall into three broad categories, i.e. rehabilitation, pharmacological, and procedural.

• It is important to understand that no treatment modality should be used alone, unless it is in itself sufficient to remedy the particular symptom/problem.

Keywords: relapsing–remitting multiple sclerosis, interferon, disease-modifying therapy, relapse prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]